PDF Version[New York, NY – June 5, 2026] – Nouveau Biosciences is proud to announce the recruitment of Deepthi Damera, Ph.D. to lead its nanochemistry programs at Nouveau Research Technologies, the company laboratory. Dr. Damera is a highly accomplished biophysicist who has spent the past decade intimately involved in all aspects of nanotechnology, from fabrication to biophysical characterization. She has been the instrumental force leading to the synthesis of the company’s lead asset, Kromastat, a highly engineered polymer nanoparticle of a potent epigenetic drug now shown to be best in class across numerous malignancies.
“Deepthi is one of those rare chemists who can seamlessly integrate herself into a highly accomplished translational drug development team, creating and optimizing drug candidates in a manner that is both unique and a testament to her team-oriented focus”, said Owen A. O’Connor, M.D., Ph.D., Founder and CEO of Nouveau Biosciences.
“I couldn’t be more excited to work with such an elite and talented team at Nouveau Biosciences”, said Dr. Damera. “Nouveau has assembled a team with incredible experience in every conceivable aspect of drug discovery and development, I am looking forward to making chemistry that has the potential to improve the care of patients with cancer”.
Nouveau’s lead candidate Kromastat, has now demonstrated “Best-in-Class” and “Best-in-Disease” activity in pancreatic cancer, aggressive leukemia and challenging T-cell lymphomas. Charles Karan, PhD., the Chief Scientific Officer of Nouveau Biosciences. commented “We look forward to following Deepthi’s leadership as we begin to reshape how drugs for cancer get developed, focusing on precision targeted drugs with markedly improved safety and efficacy”.
About Nouveau Biosciences
Nouveau Biosciences is an innovative biotechnology company that deploys a proprietary platform technology that integrates the latest scientific advances in cancer biology, genomics, computational biology and nanomedicine to produce precision targeted drugs tailored for very specific types of cancer. Its polymer-based nanoparticles are engineered to deliver both individual drugs and optimized combinations with enhanced precision, leading to improved tolerability and efficacy. The company’s lead program is clinic-ready, backed by strong intellectual property, and designed to address high-need oncology indications. The technology represents a quantum advance in the generation of highly precision targeted drugs, offering innumerable advances over technologies.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the companies’ future plans, development and licensing of cancer therapeutics, and the potential success of the collaboration. All statements other than statements of historical fact are forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements. Nouveau Biosciences undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future developments, or otherwise, except as required by law.
Media Contact
Petrina Whyte
media@nouveaubiosciences.com